401 related articles for article (PubMed ID: 19597244)
1. In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody.
Wang CH; Huang YJ; Chang CW; Hsu WM; Peng CA
Nanotechnology; 2009 Aug; 20(31):315101. PubMed ID: 19597244
[TBL] [Abstract][Full Text] [Related]
2. Anti-Neuroblastoma Activity of Gold Nanorods Bound with GD2 Monoclonal Antibody under Near-Infrared Laser Irradiation.
Peng CA; Wang CH
Cancers (Basel); 2011 Jan; 3(1):227-40. PubMed ID: 24212615
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
4. The importance of cellular internalization of antibody-targeted carbon nanotubes in the photothermal ablation of breast cancer cells.
Marches R; Mikoryak C; Wang RH; Pantano P; Draper RK; Vitetta ES
Nanotechnology; 2011 Mar; 22(9):095101. PubMed ID: 21258147
[TBL] [Abstract][Full Text] [Related]
5. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
6. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
[TBL] [Abstract][Full Text] [Related]
7. Distribution of disialoganglioside GD2-antigen and binding of anti-GD2 antibodies on spheroids of neuroblastoma cell line.
Heiss P; Bermatz S; Wehnes H; Heinzmann U; Senekowitsch-Schmidtke R
Anticancer Res; 1997; 17(4B):3145-7. PubMed ID: 9329622
[TBL] [Abstract][Full Text] [Related]
8. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.
Miederer M; McDevitt MR; Borchardt P; Bergman I; Kramer K; Cheung NK; Scheinberg DA
Clin Cancer Res; 2004 Oct; 10(20):6985-92. PubMed ID: 15501978
[TBL] [Abstract][Full Text] [Related]
9. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies.
Ohta S; Igarashi S; Honda A; Sato S; Hanai N
Anticancer Res; 1993; 13(2):331-6. PubMed ID: 8517645
[TBL] [Abstract][Full Text] [Related]
11. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
Cheung NK; Modak S
Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
[TBL] [Abstract][Full Text] [Related]
12. Selection of novel peptide mimics of the GD2 ganglioside from a constrained phage-displayed peptide library.
Horwacik I; Czaplicki D; Talarek K; Kowalczyk A; Bolesta E; Kozbor D; Rokita H
Int J Mol Med; 2007 May; 19(5):829-39. PubMed ID: 17390090
[TBL] [Abstract][Full Text] [Related]
13. Photothermal antimicrobial nanotherapy and nanodiagnostics with self-assembling carbon nanotube clusters.
Kim JW; Shashkov EV; Galanzha EI; Kotagiri N; Zharov VP
Lasers Surg Med; 2007 Aug; 39(7):622-34. PubMed ID: 17868103
[TBL] [Abstract][Full Text] [Related]
14. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.
Cheung NK; Cheung IY; Canete A; Yeh SJ; Kushner B; Bonilla MA; Heller G; Larson SM
Cancer Res; 1994 Apr; 54(8):2228-33. PubMed ID: 8174131
[TBL] [Abstract][Full Text] [Related]
15. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth.
Mujoo K; Cheresh DA; Yang HM; Reisfeld RA
Cancer Res; 1987 Feb; 47(4):1098-104. PubMed ID: 3100030
[TBL] [Abstract][Full Text] [Related]
16. Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases.
Schumacher-Kuckelkorn R; Hero B; Ernestus K; Berthold F
Pediatr Blood Cancer; 2005 Aug; 45(2):195-201. PubMed ID: 15800908
[TBL] [Abstract][Full Text] [Related]
17. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131
[TBL] [Abstract][Full Text] [Related]
18. Disialoganglioside directed immunotherapy of neuroblastoma.
Modak S; Cheung NK
Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
[TBL] [Abstract][Full Text] [Related]
19. Generation and characterization of dimeric small immunoproteins specific for neuroblastoma associated antigen GD2.
Occhino M; Raffaghello L; Burrone O; Gambini C; Pistoia V; Corrias MV; Bestagno M
Int J Mol Med; 2004 Sep; 14(3):383-8. PubMed ID: 15289889
[TBL] [Abstract][Full Text] [Related]
20. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases.
Fest S; Huebener N; Weixler S; Bleeke M; Zeng Y; Strandsby A; Volkmer-Engert R; Landgraf C; Gaedicke G; Riemer AB; Michalsky E; Jaeger IS; Preissner R; Förster-Wald E; Jensen-Jarolim E; Lode HN
Cancer Res; 2006 Nov; 66(21):10567-75. PubMed ID: 17079481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]